Drug or treatment

Imatinib clinical trials

• 26Clinical trials
• 30Countries

Newest trials

All recruiting trials (26)

• Velzatinib for advanced GIST after multiple prior TKIs

  This study tests velzatinib to see if it can shrink or slow tumors in people with metastatic or unresectable GIST who have progressed on or could not tolerate standard therapies.

  Recruiting at 3 sites Phase 2 GlaxoSmithKline · Fukuoka and 2 other locations · NCT07689201

• Velzatinib vs. Imatinib as frontline treatment for metastatic or unresectable GIST

  This trial tests velzatinib against imatinib as the first systemic therapy for adults with newly diagnosed metastatic or unresectable gastrointestinal stromal tumors to see if velzatinib can delay progression and be tolerable.

  Recruiting at 93 sites Phase 3 GlaxoSmithKline · Scottsdale, Arizona and 92 other locations · NCT07585266

• Imatinib added to artemether-lumefantrine for uncomplicated P. falciparum malaria

  This trial tests whether adding imatinib to standard artemether-lumefantrine helps people with uncomplicated Plasmodium falciparum malaria clear infections faster and limit drug-resistant parasites.

  Recruiting Phase 2 Victoria Biomedical Research Institute · Kisumu · NCT07559370

• KQB198 plus imatinib for first-line advanced or metastatic GIST

  This Phase 2 test will see if adding the experimental drug KQB198 to imatinib helps people with advanced or metastatic GIST who are starting first-line treatment.

  Recruiting at 17 sites Phase 2 Kumquat Biosciences Inc. · Los Angeles, California and 16 other locations · NCT07406633

• IDRX-42 versus sunitinib for adults with advanced gastrointestinal stromal tumors after imatinib

  This test compares IDRX-42 (GSK6042981) with sunitinib in adults with advanced or unresectable GIST who have already been treated with imatinib to see which controls the cancer better and is safer.

  Recruiting at 156 sites Phase 3 GlaxoSmithKline · Phoenix, Arizona and 155 other locations · NCT07218926

• Imatinib plus fampridine before surgery for KIT exon 11 gastrointestinal stromal tumor

  This trial tests whether adding fampridine to standard imatinib before surgery is safe and helps shrink KIT exon 11 mutant GIST tumors in adults.

  Recruiting Phase 1 University of California, San Diego · La Jolla, California · NCT07171203

• Lenvatinib for advanced GIST after imatinib, sunitinib, and regorafenib

  This trial tests whether the oral drug lenvatinib can help people with metastatic or advanced GIST whose disease has progressed on imatinib, sunitinib, and regorafenib.

  Recruiting Phase 1/2 Asan Medical Center · Seoul · NCT07096609

• Combining Imatinib and Trametinib for KRAS-mutated Solid Tumors

  This study tests if combining two cancer drugs, imatinib and trametinib, can help people with hard-to-treat solid tumors that have KRAS mutations.

  Recruiting Phase 1 China Medical University Hospital · Taichung, Taichung · NCT06962254

• Evaluating inhalable Imatinib for treating pulmonary hypertension and lung fibrosis

  This study is testing a new inhalable medication called XHALIP to see if it can help people with pulmonary hypertension and lung fibrosis feel better by improving their lung health.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Pavia · NCT06917196

• Long-term safety of Imatinib for patients with Lymphangioleiomyomatosis

  This study is testing if the cancer drug Imatinib is safe and can help women with Lymphangioleiomyomatosis by seeing how it affects their lung health over time.

  Recruiting at 2 sites Phase 1 Columbia University · New York, New York and 1 other locations · NCT06889168

• Combining ziftomenib and imatinib for advanced gastrointestinal stromal tumors

  This study is testing whether combining two medications, ziftomenib and imatinib, can help adults with advanced gastrointestinal stromal tumors who haven't responded well to imatinib alone.

  Recruiting at 32 sites Phase 1 Kura Oncology, Inc. · Birmingham, Alabama and 31 other locations · NCT06655246

• Oral Liporaxel (paclitaxel) treatment for gastrointestinal stromal tumors

  This study will test whether taking oral Liporaxel (a form of paclitaxel) can help people with advanced GIST who stopped responding to imatinib, sunitinib, and regorafenib and whose tumors have low P‑glycoprotein levels.

  Recruiting Phase 2 Asan Medical Center · Seoul, Songpagu · NCT06326346

• Combining blinatumomab with dasatinib or imatinib plus chemotherapy for young people with Ph+ or ABL-class Ph-like B‑ALL

  This pilot will see if adding three cycles of blinatumomab and a continuous tyrosine kinase inhibitor (dasatinib or imatinib) to a modified chemotherapy plan helps children, adolescents, and young adults with Ph+ or ABL-class Ph-like B‑ALL stay in remission longer.

  Recruiting at 159 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 160 other locations · NCT06124157

• Using imatinib to enhance RUNX1 activity in patients with RUNX1 mutations

  This study is testing if the medication imatinib can help people with RUNX1 mutations feel better and improve their bone marrow function.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06090669

• Comparing treatments for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  This study tests whether Ponatinib or Imatinib, both with low-dose chemotherapy, can help adults with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia feel better, and looks at how Blinatumomab can be used for those who respond well or not to these treatments.

  Recruiting at 81 sites Phase 2 Goethe University · Aachen and 84 other locations · NCT06061094

• Combination of rivoceranib and paclitaxel for advanced gastrointestinal stromal tumors

  This study is testing if a new combination of two drugs, rivoceranib and paclitaxel, can help adults with advanced gastrointestinal stromal tumors that haven't improved with standard treatments.

  Recruiting Phase 2 Asan Medical Center · Seoul, Seoul · NCT05905887

• Using imatinib to convert triple-negative breast cancer into ER-positive breast cancer

  This gives 10 days of imatinib to people with newly diagnosed triple-negative breast cancer before surgery to see if their tumors become estrogen receptor (ER)–positive.

  Recruiting Vastra Gotaland Region · Gothenburg · NCT05722795

• Using imatinib to improve outcomes in gastrointestinal stromal tumors

  This study is testing if monitoring imatinib levels can help improve the quality of life for people with gastrointestinal stromal tumors while reducing side effects.

  Recruiting Phase 2 University of Kentucky · Lexington, Kentucky · NCT05493215

• 5 years of imatinib treatment for high-risk gastrointestinal stromal tumors

  This study is testing if taking imatinib for five years after surgery can help people with high-risk gastrointestinal stromal tumors avoid their cancer coming back.

  Recruiting Phase 2 Asan Medical Center · Seoul, Seoul · NCT05385549

• Comparing the effectiveness of generic Imatinib to Glivec in treating Chronic Myeloid Leukemia

  This study is testing if a generic version of Imatinib works as well as the brand name Glivec for treating newly diagnosed adults with Chronic Myeloid Leukemia.

  Recruiting at 2 sites Hikma Pharmaceuticals LLC · Cairo and 3 other locations · NCT05282108

• Evaluating Imatinib Treatment After 10 Years for GIST Patients

  This study is testing whether stopping or continuing imatinib treatment helps people with advanced gastrointestinal stromal tumors who have been on the medication for at least 10 years.

  Recruiting at 6 sites Phase 2 Centre Leon Berard · Besançon and 12 other locations · NCT05009927

• Using Imatinib Mesylate before surgery for gastrointestinal stromal tumors

  This study is testing if taking imatinib mesylate before surgery can help people with high-risk gastrointestinal stromal tumors have better outcomes and live longer.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT04933669

• Treatment for advanced KIT-mutant melanoma using binimetinib and imatinib

  This study is testing if a combination of two medications, binimetinib and imatinib, can help people with advanced KIT-mutant melanoma feel better and manage their disease.

  Recruiting at 2 sites Phase 2 University of California, San Francisco · La Jolla, California and 1 other locations · NCT04598009

• Efficacy and safety of Radotinib for chronic myeloid leukemia patients who failed previous treatments

  This study is testing if Radotinib can help people with chronic myeloid leukemia who haven't had success with other treatments feel better and stay safe while using it.

  Recruiting at 16 sites Phase 3 Il-Yang Pharm. Co., Ltd. · Barnaul and 17 other locations · NCT03459534

• Using ponatinib for patients with chronic myeloid leukemia who didn't respond to other treatments

  This study is testing if ponatinib can help people with chronic myeloid leukemia who didn't respond to other treatments feel better and improve their health.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT01746836

• Review of Chronic Myelogenous Leukemia Patients Treated with Imatinib

  This study looks at how well imatinib works for people with Chronic Myelogenous Leukemia in everyday settings by reviewing their treatment experiences and outcomes.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT00816114

Quick answers

How many clinical trials of Imatinib are recruiting right now?

26, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 30 countries. The most sites are in United States (12 trials), South Korea (7 trials), Australia (3 trials), Canada (3 trials), China (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 13, Phase 1: 5, Phase 3: 3, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →